SHANGHAI, CHINA, October 10, 2022 – JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for its anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product relmacabtagene autoleucel injection (hereafter abbreviated as relma-cel, trade name: Carteyva®) for the treatment of adult patients with follicular lymphoma that is refractory or that relapses within 24 months of second-line or above systemic treatment (r/r FL). This is the second approved indication for relma-cel following its initial approval and launch in September last year, and it makes it the first cell immunotherapy product approved in China for the treatment of r/r FL patients.
Можда бисте волели да прочитате: ЦАР Т ћелијска терапија у Кини
This approval is based on the 6-month clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva® in adult patients with relapsed or refractory B cell non-Hodgkin lymphoma in China. The 3-month data were presented at the 63rd Годишњи састанак Америчког друштва за хематологију (АСХ) у децембру 2021. Резултати кохорте Б показали су да Цартеива® показао веома високе стопе дуготрајног одговора на болест (укупна стопа одговора (ОРР)=100%, стопа потпуног одговора (ЦРР)=85.19% у 3. месецу; ОРР=92.58%, ЦРР=77.78% у 6. месецу) и контролисани ЦАР-Т повезане токсичности код пацијената са р/р ФЛ. С обзиром на тренутно доступне третмане у Кини, Цартеива® може постати опција лечења са већим односом користи и ризика за пацијенте са р/р ФЛ, и има потенцијал да постане најбољи ЦАР-Т производ у класи.
Professor Yuqin Song, the principal investigator of RELIANCE study, Deputy Director of the Lymphoma Department, and Vice President of Универзитетска болница за рак у Пекингу, commented, “The overall response rate (ORR) of the efficacy endpoint was over 90%, and the overall safety profile was manageable. Remal-cel has become the first Имунотерапија ЦАР-Т ћелија product for the treatment of the r/r FL in China.”
Можда бисте волели да прочитате: ЦАР Т ћелијска терапија за мултипли мијелом у Кини
James Li, co-founder, chairman, and CEO of JW Therapeutics, said, “Thanks to the patients and investigators who contributed to the clinical studies of Carteyva®, и хвала регулаторима на признању Цартеиве®. We are pleased with the second approved indication, which provides a new and breakthrough treatment option for r/r FL patients. JW Therapeutics is committed to maximizing the value of Carteyva®, continuously advancing technology innovation and pipeline development, and improving the accessibility of cell имунотерапија производи."
As the first product of JW Therapeutics and the first CAR-T product approved as a Category 1 biologics product in China, relma-cel has been approved for two indications in China, including the treatment of adult patients with relapsed or refractory large B-cell лимфом (r/r LBCL) after two or more lines of systemic therapy, and the treatment of adult patients with follicular lymphoma that is refractory or that relapses within 24 months of second-line or above systemic treatment (r/r FL). JW Therapeutics is currently doing or plans to do more clinical studies on hematologic malignancies and autoimmune diseases to fully explore the clinical potential of Carteyva®. These include third-line лимфом ћелија омотача (MCL), third-line acute lymphoblastic leukemia (ALL), frontline and second-line large B-cell lymphoma (LBCL), and systemic lupus erythematosus (SLE).
О Релмацабтагене Аутолеуцел Ињецтион (трговачки назив: Цартеива®)
Relmacabtagene autoleucel injection, which is also sold under the brand name Carteyva®. It is an autologous анти-ЦД19 ЦАР-Т ћелијска имунотерапија product that was built on a CAR-T cell process platform from Juno Therapeutics, a Bristol Myers Squibb company. Being the first product of JW Therapeutics, relma-cel has been approved by the China National Medical Products Administration (NMPA) for two indications, including the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, and the treatment of adult patients with follicular lymphoma that is refractory or that relapses within 24 months of second-line or above systemic treatment (r/r FL), making it the first CAR-T product approved as a Category 1 biologics product in China. Currently, it is the only ЦАР-Т производ у Кини која је истовремено укључена у Национални значајни програм развоја нових лекова, приоритетну ревизију и одређивање напредне терапије.
Можда бисте волели да прочитате: ЦАР Т ћелијска терапија кошта у Кини
О ЈВ Тхерапеутицс
JW Therapeutics (HKEX: 2126) is an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy products, and is committed to becoming an innovation leader in cell immunotherapy. Founded in 2016, JW Therapeutics has built a world-class platform for product development in cell immunotherapy, as well as a product pipeline covering both hematologic malignancies and solid tumors. JW Therapeutics is committed to bringing breakthrough and quality cell immunotherapy products and the hope of a cure to patients in China and worldwide, and leading the healthy and standardized development of China’s cell immunotherapy industry.
